Xocova – Dosage and Administration

This medical response contains information in addition to that provided in the Xocova® (ensitrelvir) tablets, for oral use Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA). Shionogi does not recommend the use of Xocova in any manner other than as described in the Full Prescribing Information. **Please read the attached Xocova Full Prescribing Information.**

1. RECOMMENDED DOSAGE AND ADMINISTRATION

Pregnancy Evaluation Prior to Initiating XOCOVA
Verify pregnancy status of females of reproductive potential prior to initiating Xocova.[1]

Recommended Dosage
The recommended dosage of Xocova in adults and adolescents 12 years of age and older is 375 mg (three 125-mg tablets taken together) orally on Day 1 and 125 mg (one 125-mg tablet) orally on Days 2 to 5 with or without food.[1]

Begin Xocova as soon as possible and within 72 hours following contact with an individual who has COVID-19. The tablets should be taken at approximately the same time each day. If a dose of Xocova is missed, take the missed dose as soon as possible on the same day, and then take the next dose as scheduled the following day.[1]

2. CLINICAL STUDIES

SCORPIO-PEP (NCT05897541) is a completed Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical study that evaluated the safety and efficacy of ensitrelvir in the prevention of symptomatic COVID-19 in COVID-19-negative (local test) HHCs ages 12 years and older living with COVID-19-positive (local test), symptomatic index patients when compared to placebo (mITT: ensitrelvir, n=1030; placebo,n=1011).[2,3] The mITT population was defined as all randomized HHCs with central laboratory-confirmed SARS-CoV-2 negativity by RT-PCR at baseline.[2]

Participants in SCORPIO-PEP were randomized (1:1) within 72 hours of symptom onset in index patients to receive either ensitrelvir or placebo.[2] Ensitrelvir 375 mg was given orally once on Day 1, followed by ensitrelvir 125 mg orally once daily on Days 2–5 to HHCs in the active group, while placebo was given to the control group.[2] If a dose was delayed, patients were instructed to take the dose as soon as possible, but not more than 12 hours later than expected. If the dose was delayed by more than 12 hours, participants were instructed to skip the missed dose and take the next scheduled dose.[4]

3. RELEVANT PRESCRIBING INFORMATION

INDICATIONS AND USAGE

XOCOVA is indicated for post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents 12 years of age and older following contact with an individual who has COVID-19.[1]

CONTRAINDICATIONS

XOCOVA is contraindicated in patients with a history of clinically significant hypersensitivity reactions to ensitrelvir or any other components of the product.[1]

XOCOVA is contraindicated in patients taking drugs that are:

- Primarily metabolized by CYP3A for which elevated concentrations may be associated with serious and/or life-threatening reactions and
- Strong CYP3A inducers because they may significantly reduce ensitrelvir plasma concentrations, leading to the potential loss of virologic response.[1]

Please read the attached Xocova **Full Prescribing Information**. The use of Xocova in any manner other than as described in the Full Prescribing Information approved by the U.S. Food and Drug Administration (FDA) is not recommended.

ABBREVIATIONS
COVID-19, coronavirus disease
mITT, modified intent to treat
HHC, household contact
RT-PCR, Reverse Transcription–Polymerase Chain Reaction
CYP3A, Cytochrome P450, family 3, subfamily A

REFERENCES

1. Xocova® (ensitrelvir) tablets, for oral use [Prescribing Information]. Shionogi Inc.
2. Hayden FG, Shinkai M, Clark TW, et al. Ensitrelvir for Covid-19 Postexposure Prophylaxis in Household Contacts. *New England Journal of Medicine*. 2026;394(19):1905-1915. doi:10.1056/NEJMoa2509306
3. Phase 3 study of S-217622 in prevention of symptomatic SARS-CoV-2 infection (SCORPIO-PEP). NLM Identifier: NCT05897541. Last accessed June 18, 2025. https://clinicaltrials.gov/study/NCT05897541?term=scorpio-pep&rank=1.
4. Ensitrelvir Data on File 8. Shionogi Inc.

ENCLOSURE
Xocova® (ensitrelvir) tablets, for oral use [Prescribing Information]. Shionogi Inc.